

TEVA PHARMACEUTICAL INDUSTRIES LTD
Form 6-K
November 15, 2006

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

**Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

For the month of November 2006

Commission File Number 0-16174

- 1 -

Teva Pharmaceutical Industries Limited

(Translation of registrant's name into English)

5 Basel Street, P.O. Box 3190

Petach Tikva 49131 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b):
82- _____

Teva Pharmaceutical Industries Ltd.

Web Site: www.tevapharm.com

Contact: Liraz Kalif / Kevin Mannix

Teva Investor Relations

(011) 972-3-926-7281 / (215) 591-8912

FOR IMMEDIATE RELEASE

COURT OF APPEALS AFFIRMS TEVA`S GENERIC ZOCOR[®] EXCLUSIVITY

Jerusalem, Israel, November 14, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit affirmed a May 1, 2006 decision by the District Court awarding the Company 180-day exclusivity for its generic version of Merck's Zocor[®] (Simvastatin) Tablets.

On June 23, 2006, Teva received final approval from the FDA to market its Simvastatin Tablets, 5 mg, 10 mg, 20 mg, and 40 mg and immediately commenced shipment of these products. As the first company to file an ANDA containing a paragraph IV certification for these strengths, Teva was eligible to receive 180-day Hatch-Waxman statutory exclusivity to market these products. Teva`s exclusivity will run through December 20, 2006.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company.

The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: *This release contains forward-looking*

statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs

and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or

achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements.

Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate IVAX

Corporation's operations and achieve expected synergies, Teva's ability to successfully develop and commercialize additional

pharmaceutical products, the introduction of competing generic products, the impact of competition from brand-name companies that sell or

license their own brand products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the

introduction of generic product, the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva

from exploiting exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding litigation,

including that relating to the generic versions of Allegra[®], Neurontin[®] and Zithromax[®], the effects of competition on Copaxone[®] sales,

including as a result of the reintroduction of Tysabri[®] into the market, the impact of pharmaceutical industry regulation and pending

legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European

Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of

various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability

claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected

by terrorism or major hostilities, , environmental risks, fluctuations in currency, exchange and interest rates, operating results and other

factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly

or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Teva Pharmaceutical Industries Ltd.

Web Site: www.tevapharm.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: /s/ Dan Suesskind

Name: Dan Suesskind
Title: Chief Financial Officer

Date: November 14, 2006

